Cipla Limited reported a 39.2% year-on-year decline in consolidated net profit to ₹785.55 crore for the quarter ended June 30, 2026, down from ₹1,291.61 crore in the corresponding period of the previous year. The decline was driven by margin contraction and exceptional costs related to new labour codes, even as revenue registered modest growth. The Board of Directors approved the unaudited financial results at its meeting held on July 23, 2026.

Q1 Financial Performance

Total revenue from operations for the quarter stood at ₹7,119.28 crore, a 2.3% increase compared to ₹6,957.47 crore in Q1FY26. However, total expenses rose to ₹6,248.25 crore from ₹5,446.10 crore year-on-year. The company reported an exceptional loss of ₹275.91 crore in the previous fiscal year ended March 31, 2026, primarily due to an incremental gratuity and leave liability arising from the implementation of the New Labour Codes effective November 21, 2025.

Operational and Regulatory Updates

The company noted that effective April 1, 2026, it changed its presentation policy for marketing and promotional expenditures, now recording them as a reduction from Revenue from Operations rather than under Other Expenses. This change impacts revenue comparability but does not affect Profit for the period or Earnings per Share. Additionally, the paid-up equity share capital increased to ₹161.57 crore during the quarter following the allotment of shares under employee stock option schemes.

Cipla continues to face demand notices from the National Pharmaceutical Pricing Authority (NPPA) regarding alleged overcharges. The aggregate amount under litigation stands at ₹2,011 crore, comprising a principal of ₹863 crore and interest of ₹1,148 crore. The company has stated it expects a favourable outcome and has not made any provisions for these demands.

Segment Performance

One India delivered its highest-ever quarterly revenue of ₹3,452 crore, growing 12% year-on-year. This performance was driven by double-digit growth in chronic therapies such as Respiratory, Urology, Anti-diabetes, and Cardiac. The company maintained its rank as the second-largest player in overall chronic therapies, with the chronic mix improving to 60.4%. Key brands like Foracort, Duolin Syncrobreathe, and Doloneuron contributed to the growth.

North America reported revenue of $162 million, highlighted by the launch of the first AB-rated gVentolin with Complex Generic Technology (CGT). One Africa revenue stood at $103 million, up 1% year-on-year, with South Africa's private business growing faster than the market. Emerging Markets and Europe recorded revenue of $106 million, a 5% increase, continuing their growth trajectory.

Cipla and Dr. Reddy's are among the Indian pharmaceutical firms positioned to benefit from the emerging GLP-1 opportunity in the domestic market, according to a Financial Express report. The growing interest in GLP-1 class drugs, which are used in the treatment of diabetes and obesity, is expected to provide a meaningful boost to the domestic business of these companies.

Semaglutide Patent Expiry Opens New Doors

A key development supporting this opportunity is the expiry of semaglutide's patent in the domestic market in March. This patent expiry has allowed Indian pharmaceutical companies to enter the semaglutide segment, enabling them to launch generic versions of the drug and compete in a space that was previously restricted.

Domestic Business Outlook

The GLP-1 segment represents a significant growth avenue for Indian pharma companies in the domestic formulations market. With semaglutide's patent now expired domestically, companies like Cipla and Dr. Reddy's have the opportunity to capture a share of this rapidly growing therapeutic category. The development is seen as a positive catalyst for the domestic business of these pharmaceutical firms, as demand for GLP-1 drugs continues to rise in India.